Journal article

Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults

Terry Nolan, Hartley Garfield, Anil Gupta, Murdo Ferguson, Helen Marshall, Diego D’Agostino, Daniela Toneatto

Open Forum Infectious Diseases | Oxford University Press (OUP) | Published : 2017


Abstract Background This phase 3b, open label, controlled, multi-center, extension study (NCT02446743) assessed the persistence of bactericidal activity at 4 years post-primary vaccination with a recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) in adolescents who participated in the parent study NCT01423084 and their response to a booster dose, compared with that in vaccine-naïve healthy controls. Methods Adolescents and young adults previously primed with 4CMenB (2 doses; following a 0,1-month schedule) in study NCT01423084 (group 3B) and vaccine-naïve ..

View full abstract

University of Melbourne Researchers

Citation metrics